Indica Labs invites you to attend our 2018 Basel User Group Meeting Thursday May 17, 2018Airport Hotel BaselBasel Switzerland12:00 PM – 6:00 PM The event
INDICA LABS 1ST BASEL QUANTITATIVE PATHOLOGY USER MEETING Read More »
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by
PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance Read More »
Indica Labs invites you to attend a session in our 2018 US User Group Meeting Series. Each session will feature customer presenters representing diverse organizations, including
Indica Labs 2018 US User Group Meeting Series Read More »
Epidemiologic studies report improved breast cancer survival in women receiving ketorolac (Toradol®) for post-operative pain relief compared to other analgesics. Ketorolac is a racemic drug.
Abstract Conflicting reports regarding whether high tumor-associated neutrophils (TAN) are associated with outcomes in colorectal cancer (CRC) exist. Previous investigators have counted TAN using non-neutrophil-specific
Abstract Importance The programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway play an important immunosuppressive role in cancer and chronic viral infection,
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma Read More »
HALO and HALO Link users representing a diverse set of organizations, including pharma, biotech, and academic medical centres across Europe will discuss how they are
Indica Labs 2nd London Quantitative Pathology User Meeting Read More »
Corrales, NM – October 24, 2017 – Indica Labs, the leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce
Corrales, NM – October 5, 2017 – Indica Labs Inc headquartered in Corrales, New Mexico, is pleased to announce the selection of the newly developed
Portland, OR – September 29, 2017 – MolecularMD, a provider of molecular and tissuebased clinical trial assays and diagnostics for oncology based drug development programs,
